Novavax (NVAX) Cash & Equivalents Growth (5y) (2015 - 2026)

Novavax (NVAX) Cash & Equivalents Growth (5y) (2015 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Novavax 1.23 Bn 440.77 Mn 108.82 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 48.03%
Dec 31, 2025 -35.02%
Sep 30, 2025 31.89%
Jun 30, 2025 -9.78%
Mar 31, 2025 9.13%
Dec 31, 2024 29.24%
Sep 30, 2024 51.80%
Jun 30, 2024 15.83%
Mar 31, 2024 135.55%
Dec 31, 2023 51.96%
Sep 30, 2023 63.05%
Jun 30, 2023 118.61%
Mar 31, 2023 99.96%
Dec 31, 2022 -37.30%
Sep 30, 2022 -36.47%
Jun 30, 2022 -19.39%
Mar 31, 2022 74.95%
Dec 31, 2021 -39.72%
Sep 30, 2021 74.43%
Jun 30, 2021 87.56%